Additionally, in advanced G/GEJ adenocarcinoma, clinical trials of fibroblast growth factor receptor 2 (FGFR2)-targeted antibodies are underway, and FGFR2b may also become one of the future treatment targets and biomarkers [35,36]. The gene discussed is FGFR2; the disease is gastroesophageal junction adenocarcinoma.